Zoetis Inc.

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-12-10 pm EST			5-day change	1st Jan Change
118.07 ^USD	+2.00%		-3.67%	-27.53%

Dec. 10	HSBC Adjusts Zoetis Price Target to $140 From $180, Maintains Buy Rating	MT
Dec. 09	Barclays Initiates Zoetis at Equalweight With $136 Price Target	MT

Tranche Update on Zoetis Inc.'s Equity Buyback Plan announced on August 1, 2024.

Published on 11/04/2025 at 03:03 pm EST

S&P Capital IQ

Zoetis Inc.

+2.00%

From July 1, 2025 to September 30, 2025, the company has repurchased 2,489,762 shares, representing 0.56% for $376.99 million. With this, the company has completed the repurchase of 9,265,999 shares, representing 2.07% for $1,500.24 million under the buyback announced on August 1, 2024.

Latest news about Zoetis Inc.

Dec. 10	HSBC Adjusts Zoetis Price Target to $140 From $180, Maintains Buy Rating	MT
Dec. 09	Barclays Initiates Zoetis at Equalweight With $136 Price Target	MT
Dec. 05	Zoetis Says Health Canada Approves Long-Lasting Cat Osteoarthritis Drug	MT
Dec. 05	Zoetis Inc. Receives Health Canada Approval for Portela?? (Relfovetmab Injection) to Alleviate Pain Associated with Osteoarthritis in Cats	CI
Dec. 05	Zoetis receives Health Canada approval for Portela (Relfovetmab injection)	RE
Dec. 04	Zoetis Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-04-2025 09:30 AM
Dec. 03	TD Cowen Adjusts Zoetis Price Target to $150 From $189, Maintains Buy Rating	MT
Dec. 03	Rothschild & Co Redburn Adjusts Price Target on Zoetis to $165 From $195, Maintains Buy Rating	MT
Dec. 02	Zoetis Inc. - Special Call
Nov. 26	Zoetis receives European Commission marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs	RE
Nov. 26	Zoetis Inc. Receives European Commission Marketing Authorization for Lenivia®? (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs	CI
Nov. 21	KeyBanc Initiates Zoetis at Sector Weight	MT
Nov. 18	Traders Strap In, Again
Nov. 18	Stifel Adjusts Price Target on Zoetis to $130 From $140, Maintains Hold Rating	MT
Nov. 18	Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast…
Nov. 12	BTIG Adjusts Price Target on Zoetis to $160 From $200, Maintains Buy Rating	MT
Nov. 10	Zoetis Inc. acquired Veterinary Pathology Group Limited.	CI
Nov. 10	Piper Sandler Adjusts Price Target on Zoetis to $190 From $215	MT
Nov. 07	Morgan Stanley Adjusts Zoetis Price Target to $175 From $211	MT
Nov. 05	Leerink Partners Adjusts Zoetis Price Target to $130 From $152, Maintains Market Perform Rating	MT
Nov. 05	JPMorgan Adjusts Zoetis Price Target to $200 From $230, Maintains Overweight Rating	MT
Nov. 05	UBS Adjusts Price Target on Zoetis to $141 From $158, Maintains Neutral Rating	MT
Nov. 05	BNP Paribas Exane Adjusts Zoetis Price Target to $197 From $223, Maintains Outperform Rating	MT
Nov. 05	Jefferies & Co Adjusts Zoetis Price Target to $170 From $180, Maintains Buy Rating	MT
Nov. 04	Tranche Update on Zoetis Inc.'s Equity Buyback Plan announced on August 1, 2024.	CI

Chart Zoetis Inc.

Duration

Period

ZTS: Dynamic Chart

Company Profile

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - companion animal (67.8%): cats and dogs (95.5% of net sales) and horses (4.5%); - livestock (31.3%): cattle (52.8% of sales), poultry (18.2%), swine (17.8%), fish (8.4%) and other (2.8%); - other (0.9%). Net sales break down by family of products into parasiticides (23.3%), vaccines (19.7%), dermatological products (17.9%), anti-infectives (11.9%), pain relievers (9.2%), diagnostic products (4.2%), medicated feed additives (3.2%) and other (10.6%). At the end of 2024, the group has 22 production sites worldwide. The United States accounts for 54.8% of net sales.

Employees

13,800

Sector

Pharmaceuticals

Calendar

Feb. 16 - Q4 2025 Earnings Release (Projected)

More about the company